How long does Mazdutide stay in your system?
Mazdutide has a published half-life of 150.9 to 403.5 hours (6.3 to 16.8 days). By the standard pharmacology rule of thumb, a drug is about 97% eliminated after roughly five half-lives, which here works out to between 31.4 and 84.1 days (4.5 to 12 weeks). The range is wide because it spans dose cohorts after a first dose, and a later higher-dose trial reported a spread up to 1075.7 hours.
Source: Ji et al., eClinicalMedicine 2021 (PMID 34430840) · Peer-reviewed · measured: subcutaneous · dataset reviewed September 23, 2026
What is the half-life of Mazdutide?
Mazdutide's published half-life is 150.9 to 403.5 hours, or 6.3 to 16.8 days, from a study in eClinicalMedicine in 2021, measured after subcutaneous injection. Mazdutide is an investigational dual agonist of the GLP-1 and glucagon receptors, derived from the gut hormone oxyntomodulin and developed by Innovent Biologics under licence from Eli Lilly.
That range is not a mean with a little uncertainty around it. It is the spread across dose cohorts, estimated by non-compartmental analysis after a first dose. On the five half-life rule it translates into anywhere from about a month to nearly three months, a very wide window for a single compound.
How much Mazdutide is left after each half-life?
Each half-life removes half of whatever is left, so the percentages are pure arithmetic and the same for any compound; only the clock changes. For Mazdutide, one half-life is 6.3 to 16.8 days. The rows below run that forward for a single amount with nothing added.
| Half-lives elapsed | Time elapsed | Remaining | Cleared |
|---|---|---|---|
| 1 | 6.3 to 16.8 days | 50% | 50% |
| 2 | 12.6 to 33.6 days | 25% | 75% |
| 3 | 18.9 to 50.4 days (2.7 to 7.2 weeks) | 12.5% | 87.5% |
| 4 | 25.2 to 67.3 days (3.6 to 9.6 weeks) | 6.25% | 93.75% |
| 5 | 31.4 to 84.1 days (4.5 to 12 weeks) | 3.13% | 96.88% |
| 6 | 37.7 to 100.9 days (5.4 to 14.4 weeks) | 1.56% | 98.44% |
| 7 | 44 to 117.7 days (6.3 to 16.8 weeks) | 0.78% | 99.22% |
Why do the numbers differ between sources?
Long-acting peptides have long terminal tails, and how much of the tail a study captures can depend on its dose and how long it samples. The 2021 data gave 150.9 to 403.5 hours. A later higher-dose trial reported a considerably wider spread, up to 1075.7 hours. That reflects the tail of the curve, not a different molecule.
Non-compartmental analysis after a single first dose is a standard approach, but it is sensitive to exactly these tails. That is why this page shows the time column as a range, and why it does not use the 1075.7 hour figure in the table: it comes from a different trial and dose range.
What does a half-life not tell you?
It does not settle whether mazdutide behaves the same at higher doses or with repeated administration, and the gap between the two trials argues for caution in assuming it does. Nor does it describe the glucagon receptor effects, thought to raise energy expenditure and reduce liver fat, which have their own time course.
It also says little about populations beyond the ones studied. Development is most advanced in China, and pharmacokinetic values can shift between the populations in which they are measured. The legal status page covers where mazdutide stands with regulators.
Can you run the numbers yourself?
The estimator applies the same decay arithmetic to any half-life, starting amount and time you enter. It opens with Mazdutide's published value loaded. Type another figure to see how sensitive the result is to it.
Published value: 150.9 to 403.5 hours (6.3 to 16.8 days) (Subcutaneous) · Ji et al., eClinicalMedicine 2021 (PMID 34430840) · Compound profile
Show the math
What are the limits of this estimate?
Everything above is a single-compartment approximation: one pool of drug, falling by the same fraction in every interval. Real elimination varies with kidney and liver function, body composition, formulation and route, and a published figure describes only the route and the people it was measured in. Many compounds also show a fast distribution phase before the slower elimination the table describes.
A half-life is not a dosing schedule. Labelled intervals come from clinical trials that measured outcomes and tolerability, and nothing on this page suggests when to take, repeat or stop anything. Whether Mazdutide is out of your system for drug-testing purposes is a different question again. Tests often look for metabolites rather than the parent compound, and the answer depends on the assay, its sensitivity and the sample type, none of which a plasma half-life captures.
FAQ.
Why is mazdutide's half-life range so wide?
The figure of 150.9 to 403.5 hours spans several dose cohorts, estimated by non-compartmental analysis after a first dose. Long-acting peptides have long terminal tails, and a later higher-dose trial reported values up to 1075.7 hours. The range reflects that tail, not a different molecule.
How long does mazdutide take to clear by the five half-life rule?
Between about 754.5 and 2017.5 hours, roughly 31 to 84 days, using the 2021 range. That is a single-compartment estimate for a single dose, and the later trial's longer tail suggests the upper end could be longer still.
Is mazdutide the same as survodutide?
No. Both are GLP-1 and glucagon dual agonists, but they are different molecules from different developers. Survodutide has no published numeric human half-life in our dataset, so the mazdutide figure cannot be borrowed for it.
For what the evidence on Mazdutide actually shows, read the Mazdutide profile. For approval and regulatory position, see is Mazdutide legal. The half-life reference lists every sourced value side by side, including the compounds where a number circulates online with no reliable human data behind it.